The market for Human Chorionic Gonadotropin (HCG) was estimated to be worth USD 1.8 billion in 2024 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.9% to reach USD 3.6 billion by the end of 2034.
Human Chorionic Gonadotropin Industry Demand
Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone widely used in reproductive medicine and hormone-related therapies. It is either recombinantly produced or derived from urine sources, and is commonly used in fertility treatments to stimulate ovulation in women and increase testosterone in men with hypogonadism.
The market is being shaped by strong demand across both developed and emerging economies due to its cost-effectiveness, long shelf life, and ease of administration, especially with the growing availability of self-injection pens. The rise in infertility cases, government-supported reproductive health programs, and the shift toward outpatient and home-care settings are also fueling HCG product consumption. Furthermore, the increased use of HCG in male hypogonadism therapy and sports-related hormone management adds an additional layer of demand.
Request Sample@ https://www.researchnester.com/sample-request-7956
Human Chorionic Gonadotropin Market: Key Growth Drivers & Major Restraint
Growth Drivers –
1. Outsourcing of Biomanufacturing and API Supply:
Pharmaceutical companies are increasingly outsourcing HCG production to reduce costs and ensure steady API supplies. This has expanded global access and encouraged regional players to scale up production.
2. Growing Prevalence of Infertility and Hormonal Disorders:
Rising rates of infertility, especially among women aged 30–45, and increasing diagnosis of male hypogonadism are significantly driving the demand for HCG-based therapies.
3. Technological Advancements in Drug Delivery:
The development of FDA-approved self-administered HCG pens and sublingual tablets has boosted user compliance and expanded accessibility for patients seeking non-invasive treatment options.
Restraint –
• Stringent Regulatory Frameworks & Ethical Concerns:
Despite medical necessity, regulatory hurdles related to biological sourcing, storage, and standardization—as well as concerns over misuse in bodybuilding or non-medical scenarios—continue to challenge market penetration and approval cycles in several regions.
Human Chorionic Gonadotropin Market: Segment Analysis
Segment Analysis by Product Type –
• Recombinant HCG: Growing preference due to its purity, safety, and scalable production. Increasing acceptance in developed markets where biosafety and consistency are highly prioritized.
• Urinary-Derived HCG: Widely used in low- and middle-income regions due to affordability. Government procurement and bulk production are key demand contributors.
Segment Analysis by Application –
• Fertility Treatment: Core driver of HCG demand; widely used in assisted reproductive technology (ART), including IVF and ovulation induction protocols.
• Hypogonadism Therapy: Rising cases of low testosterone among men and increasing awareness of male fertility have elevated this segment’s importance.
• Other Therapeutic Uses: Includes niche areas like cryptorchidism in boys, hormone replacement therapy, and weight-loss programs—though controversial in some cases.
Segment Analysis by End‑User –
• Fertility Clinics: Primary revenue generators, particularly in urban areas and countries with advanced ART programs.
• Hospitals: Major consumers in public and private healthcare systems, especially where insurance coverage supports hormonal therapies.
• Research Institutes: Contribute to innovation and biosimilar development, especially in the recombinant space. Demand tied to clinical trial and lab-scale usage.
Human Chorionic Gonadotropin Market: Regional Insights
North America:
North America accounts for a major share of the HCG market, supported by strong awareness, advanced fertility centers, and insurance-backed treatments. The U.S. leads in adopting recombinant HCG products, with growing demand for self-injection and home-based therapies. Clear regulations and FDA approvals further drive regional expansion.
Europe:
Europe’s market is characterized by strong public healthcare infrastructure and wide acceptance of both recombinant and urinary-derived products. Sustainability in production, especially from companies like Ferring and IBSA, has become a major selling point. Demand is fueled by government-supported reproductive programs and a growing geriatric population.
Asia-Pacific (APAC):
APAC is witnessing exponential growth, supported by population size, rising infertility rates, and supportive national health schemes. Countries like India and China are becoming major production hubs, offering affordable products to both local and global markets. Urbanization and increased medical tourism are also catalyzing demand.
Top Players in the Human Chorionic Gonadotropin Market
Prominent players in the Human Chorionic Gonadotropin market include Merck Group, Ferring Pharmaceuticals, Livzon Pharmaceutical Group, Fresenius Kabi, LG Chem, Sanzyme Biologics, IBSA Institut Biochimique, Bharat Serums & Vaccines, Hengrui Medicine, Gedeon Richter, Zydus Lifesciences, Teva Pharmaceutical, Biosidus, CCPBio, Xbrane Biopharma, and MSD. These companies are actively engaged in innovation, biosimilar development, global expansion, and strategic partnerships to address the rising global demand for HCG-based therapies.
Access Detailed Report@ https://www.researchnester.com/reports/human-chorionic-gonadotropin-market/7956
Contact for more Info:
AJ Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
- Tanu Sharma's blog
- Log in or register to post comments